Better Than The Berkshire Hathaway? Danaher's Value
Chris DeMuth Jr. • 69 Comments
Chris DeMuth Jr. • 69 Comments
Yesterday, 7:53 AM
- Danaher (NYSE:DHR) expects to complete the spin-off of Fortive Corporation on July 2, 2016.
- The move will see common stockholders will receive a stock dividend of one share of Fortive common stock for every two shares of Danaher common stock they hold as of the spin-off record date, which is expected to be June 15, 2016.
- Fortive will be comprised of two segments, Professional Instrumentation and Industrial Technologies.
Thu, Apr. 21, 7:45 AM
- Net earnings of $1.08. $0.91 per share in the same quarter a year ago.
- "We were pleased with our start to 2016 as our team continued to outperform in the face of uncertain and challenging economic conditions," CEO Thomas Joyce declared.
- The company anticipates diluted net EPS for FQ2 to be in a range of $1.19-$1.23, and increased its expectations for full year diluted net earnings to $4.85-$4.98.
- Q1 results
Thu, Apr. 21, 6:02 AM
Wed, Apr. 20, 5:30 PM
- ADS, ALK, AZZ, BANC, BBT, BHE, BIIB, BK, BX, CFG, CLS, COL, DAN, DGX, DHI, DHR, DOV, DST, ERIC, FAF, FCS, FITB, GM, GMT, HOMB, IMAX, JAKK, JCI, KCG, KEY, LAD, LAZ, LUV, MAN, MDSO, MDWD, NUE, NVR, NVS, PBCT, PHM, PII, POOL, PPG, PVTB, RS, SHW, SILC, SNA, SON, STC, SWK, SYNT, TCB, TRV, UA, UNP, USG, UTEK, VZ
Thu, Apr. 14, 1:36 PM
- Morgan Stanley identifies 30 stocks for investors to snap up and hold until 2019.
- The investment firm narrowed its list by focusing on strong brands/franchises with distinct competitive advantages, while also scoring strong on pricing power, cost efficiency, and growth.
- The MS list includes Accenture (NYSE:ACN), Alphabet, Amazon.com, Apple, Blackstone Group (NYSE:BX),Comcast (NASDAQ:CMCSA), Constellation Brands (NYSE:STZ), CVS Health (NYSE:CVS), Danaher (NYSE:DHR), Dollar General (NYSE:DG), Estee Lauder (NYSE:EL), Facebook, First Republic Bank (NYSE:FRC), HCA Holdings (NYSE:HCA), International Business Machines (NYSE:IBM), JPMorgan Chase, L Brands (NYSE:LB), Mettler-Toledo (NYSE:MTD), NextEra Energy (NYSE:NEE), Nike (NYSE:NKE), Panera Bread (NASDAQ:PNRA), Philip Morris International (NYSE:PM), Public Storage (NYSE:PSA), Ross Stores (NASDAQ:ROST), SBA Communications(NASDAQ:SBAC), ServiceMaster (NYSE:SERV), T-Mobile (NASDAQ:TMUS), Visa (NYSE:V), WhiteWave Foods (NYSE:WWAV), and Zayo Group Holdings (NYSE:ZAYO).
Mon, Apr. 4, 12:26 PM
- General Electric (GE -1.9%) sinks after shares are downgraded to Market Perform from Outperform at Bernstein, which cites valuation concerns after the stock recently hit an eight-year high at $32.
- Bernstein sees risks of rising competition in several of GE's businesses, that growth in its health care segment will be challenged by pricing pressure, and the success of its power and aviation businesses are priced in.
- The firm says many sources of upside are now 'baked into' the current share price" even as GE still has many of the same risks, ranging from Alstom integration and power demand to a longer duration oil and gas business down-cycle to a potential air pocket in aviation within the next few years.
- Bernstein also downgrades Danaher (DHR -1.7%) and IDEX (IEX -1.6%) to Market Perform from Outperform on valuation.
- Now read General Electric: A major buy signal just flashed
Tue, Feb. 23, 4:35 PM
Fri, Jan. 29, 5:47 PM
- The best-performing U.S. stock over the past 30 years is one that few have heard of: Balchem (NASDAQ:BCPC), a New York-based maker of flavorings, fumigating gases and nutritional additives for animal feed.
- Since the end of 1985, Balchem has gained an average of 26.2%/year - a total gain of 107,099% - vs.10.3% for the S&P 500.
- But with flattening profitability and shares at a lavish 27x earnings, Balchem looks expensive for now, WSJ's Jason Zweig writes.
- Over the past 30 years, 44 U.S. stocks generated cumulative total returns of 10,000% or more; the 10 behind Balchem are HD, AMGN, NKE, UNH, DHR, OTCPK:ATCD, KSU, JKHY, AAPL and MO.
Tue, Jan. 26, 8:37 AM
- Net earnings of $1.27 per share vs. $1.12 per share in the same quarter a year ago.
- "During the quarter, the team delivered double-digit earnings growth, significantly expanded core operating margins, generated record free cash flow and announced several bolt-on acquisitions," CEO Thomas Joyce said. "Despite the more challenging economic landscape, particularly in our industrially-oriented markets, we continue to execute well."
- The company anticipates diluted net earnings per share for FQ1 of 2016 to be in a range of $1.00-$1.04, and full year diluted net earnings to be in a range of $4.80-$4.95.
- Q4 results
Tue, Jan. 26, 6:04 AM
- Danaher Corporation (NYSE:DHR): Q4 EPS of $1.27 in-line.
- Revenue of $5.88B (+12.4% Y/Y) misses by $130M.
Mon, Jan. 25, 5:30 PM
Dec. 22, 2015, 3:15 PM
- Investors in industrial stocks should favor "safe havens” such as General Electric (GE +0.5%), Roper Technologies (ROP +1.2%), Honeywell (HON +1.6%), Ametek (AME +0.7%), Danaher (DHR +0.4%) and Xylem (XYL +0.9%) - "self-help stories with capital allocation/M&A catalysts, margin strength, pockets of end market positives, and low/manageable oil exposures" - RBC analysts say.
- Valuations look stretched in these safe havens, but the investment strategy at the outset of a rate hike cycle should always be to "inch up the quality curve” and start playing a bit more defensively, RBC says, adding that it sees incremental risk to oil-exposed stocks such as Underperform-rated Flowserve (FLS +1.2%) and SPX Flow (FLOW +2%).
Dec. 17, 2015, 9:05 AM
- Barclays ups its price target on Danaher (NYSE:DHR) to $97 from $94, but maintained its "overweight" rating on the stock.
- "DHR remains the 'gold standard' of industrial companies as it relates to pretty much everything we care about: quality of portfolio, quality of management, quality of processes, and willingness to change/adapt with market conditions and investor interests," the firm said.
- Barclays also expects the company to finish the year with a top-quartile operating performance.
- Previously: Danaher reaffirms 2015 guidance, initiates 2016 outlook (Dec. 16 2015)
Dec. 16, 2015, 7:56 AM
- Ahead of its investor day, Danaher (NYSE:DHR) reaffirms its adjusted diluted net earnings per share guidance of $1.25-$1.29 for the fourth quarter 2015.
- The company also anticipates that 2016 adjusted diluted net earnings per share will be in a range of $4.80-$4.95, which assumes core revenue growth between 2%-3%.
- Danaher's investor day webcast kicks off at 11:00 a.m. ET.
- DHR -0.6% premarket
Dec. 14, 2015, 10:02 AM
- Shares of Newell Rubbermaid (NYSE:NWL) fall 5% after the company formally announces a merger with Jarden (JAH +4%). The price tag may have been slightly higher than anticipated.
- The merger will create a $16B consumer goods juggernaut called Newell Brands which could have broad implications across the sector.
- Within the consumer products sector, there are marginal gains today for NACCO Industries (NC +1%), Spectrum Brands (SPB +0.6%), Stanley Black & Decker (SWK +0.4%), Clorox (CLX +0.5%), Kimberly-Clark (KMB +1.6%), and Danagher (DHR +0.2%) after the big merger announcement.
- Previously: Newell Rubbermaid and Jarden agree to combine (Dec. 14 2015)
Dec. 11, 2015, 4:25 PM
- Voyager Therapeutics (NASDAQ:VYGR) initiated with Outperform rating and $36 (52% upside) price target by Wedbush.
- Perrigo (NYSE:PRGO) upgraded to Buy from Hold with $170 (15% upside) price target by Argus.
- Myriad Genetics (NASDAQ:MYGN) upgraded to Neutral from Sell by Goldman Sachs. Price target raised to $94 (123% upside) from $72.
- Abbott Laboratories (NYSE:ABT) upgraded to Buy from Hold by Jefferies. Price target raised to $55 (24% upside) from $49.
- Eli Lilly (NYSE:LLY) upgraded to Buy from Hold by Deutsche Bank. Price target raised to $99 (19% upside) from $85.
- PerkinElmer (NYSE:PKI) downgraded to Sell from Neutral. Price target lowered to $44 (12% downside risk) from $55. LabCorp (NYSE:LH) downgraded to Neutral from Buy. Price target lowered to $126 (4% upside) from $142. Danaher (NYSE:DHR) downgraded to Neutral from Buy. Price target lowered to $103 (11% upside) from $104. All by Goldman Sachs.
- Bluebird bio (NASDAQ:BLUE) downgraded to Equal Weight from Overweight by Morgan Stanley. Price target lowered to $69 (16% upside) from $143. Maintained at Outperform by Wedbush. Price target lowered to $117 (96% upside) from $165. Downgraded to Neutral from Buy by Roth Capital. Price target lowered to $62 (4% upside) from $121. Maintained at Overweight at Piper Jaffray. Price target unchanged at $204 (242% upside).
Danaher Corp. designs, manufactures and markets professional, medical, industrial and commercial products and services. It operates in five business segments: Test and Measurement, Environmental, Life Sciences and Diagnostics, Dental and Industrial Technologies. The Test and Measurement segment... More
Country: United States
Other News & PR